TherapeuticsMD, Inc. (TXMD) Receives Notice Of Allowance For Patent Covering Platform Technology Of Oral Combination Bioidentical 17ß-Estradiol And Progesterone
12/9/2013 10:17:22 AM
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (NYSE MKT:TXMD), a women’s healthcare company ("TherapeuticsMD" or the "Company"), announced today that it received a Notice of Allowance from the U.S. Patent and Trademark Office pertaining to its U.S. Patent Application 13/684,002 - "Natural Combination Hormone Replacement Formulations and Therapies." This Patent Application covers the Company’s platform technology TX 12-001-HR, its oral bioidentical 17ß-estradiol and progesterone combination drug candidate.
Help employers find you! Check out all the jobs and post your resume.
comments powered by